Keynote at World CNS Summit and Company Presentation at Noble Healthcare Conference

FRAMINGHAM, Mass., January 21, 2019 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that the company will be making presentations at upcoming healthcare industry conferences, highlighting the company’s scientific discoveries and drug development for Alzheimer’s and neurodegenerative diseases.

The presentations will emphasize Alzheon’s pioneering Precision Medicine approach to Alzheimer’s disease with its Phase 3-ready drug candidate, ALZ-801. The details of the upcoming presentations are as follows:

Event: Noble Healthcare Conference

  • Panel Presentation: Researching the Cause of Alzheimer’s Disease – Quest for a Cure
  • Speaker: Martin Tolar, MD, PhD, Founder, President and CEO, Alzheon, Inc.
  • Date: Monday, January 28, 2019
  • Location: Ft Lauderdale, FL

Event: 7th World CNS Summit Targeting Neurodegenerative Disorders

  • Presentation: ALZ-801 Phase 3-Ready Program: A Targeted Therapy for Alzheimer’s Disease
  • Speaker: Martin Tolar, MD, PhD, Founder, President and CEO, Alzheon, Inc.
  • Date: Wednesday, February 20, 2019
  • Location: Boston, MA

“Alzheon is the frontrunner in developing the first effective treatment for Alzheimer’s that can slow or stop the progression of the disease. Our approach prevents the formation of toxins that can lead to memory loss and drive the onset and progress of Alzheimer’s symptoms. Our safe oral pill ALZ-801 augments the body’s natural mechanism for preventing the formation of these toxins and facilitating clearance from the brain. We look forward to these industry conferences where we can share our insights in Alzheimer’s disease and progress with ALZ-801 with colleagues in the drug development field,” said Dr. Tolar.

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of beta amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a Precision Medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.


Kathryn Morris
The Yates Network